The Efficacy and Safety of Nirmatrelvir/Ritonavir Against COVID-19 in Elderly Patients

The Efficacy and Safety of Nirmatrelvir/Ritonavir Against COVID-19 in Elderly Patients

Zheng Xiang,&ast; Yueyuan Wang,&ast; Yuchen Qu, Bo Lv, Junping Han, Delai Xu, Kai Fan, Cunjin Su, Zhu Shen Department of Pharmacy, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, People’s Republic of China&ast;These authors contributed equally to this workCorrespond...

Full description

Bibliographic Details
Main Authors:	Xiang Z, Wang Y, Qu Y, Lv B, Han J, Xu D, Fan K, Su C, Shen Z
Format:	Article
Language:	English
Published:	Dove Medical Press 2024-01-01
Series:	International Journal of General Medicine
Subjects:	nirmatrelvir/ritonavir covid-19 elderly patients effectiveness
Online Access:	https://www.dovepress.com/the-efficacy-and-safety-of-nirmatrelvirritonavir-against-covid-19-in-e-peer-reviewed-fulltext-article-IJGM

Similar Items

Clinical Effectiveness of Ritonavir-Boosted Nirmatrelvir—A Literature Review
by: Sydney Paltra, et al.
Published: (2024-01-01)

Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world studyResearch in context
by: Shuxia Wang, et al.
Published: (2024-03-01)

Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir
by: Karolina Akinosoglou, et al.
Published: (2022-11-01)

Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
by: Jiayue Lu, et al.
Published: (2023-05-01)

Managing nirmatrelvir/ritonavir (Paxlovid) interactions in general practice
by: Dagmara Mirowska-Guzel, et al.
Published: (2023-09-01)

Nirmatrelvir–Ritonavir Reduced Mortality in Hospitalized Patients with COVID-19 During the Omicron Outbreak: Real-World Evidence from Beijing
by: Zhang Y, et al.
Published: (2024-04-01)

Efficacy and safety of Nirmatrelvir/Ritonavir for treating the Omicron variant of COVID-19
by: Chaochao Qiu, et al.
Published: (2023-07-01)

The Development of an Oral Solution Containing Nirmatrelvir and Ritonavir and Assessment of Its Pharmacokinetics and Stability
by: Lili Wang, et al.
Published: (2024-01-01)

Safety, efficacy, and pharmacokinetics of nirmatrelvir and ritonavir in patients with severe COVID-19 and renal impairment: A case report
by: Ren Zheng, et al.
Published: (2024-03-01)

Post nirmatrelvir/ritonavir erythema multiforme in a patient with coronavirus disease infection
by: José Wagner Leonel Tavares-Júnior, et al.
Published: (2023-06-01)

Comparison of Azvudine and Nirmatrelvir/Ritonavir and Combined Use in Patients with COVID-19
by: Hu CY, et al.
Published: (2023-12-01)

Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study
by: Zhao X, et al.
Published: (2023-09-01)

Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study
by: Qinqin Zhao, et al.
Published: (2023-07-01)

Viral rebound and safety of nirmatrelvir/ritonavir for lung-transplant recipients infected with SARS-CoV-2
by: Hui Li, et al.
Published: (2023-10-01)

Molnupiravir and Nirmatrelvir/Ritonavir: Tolerability, Safety, and Adherence in a Retrospective Cohort Study
by: Maria Mazzitelli, et al.
Published: (2023-01-01)

Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
by: Samuel Theodorus Sutanto, et al.
Published: (2022-12-01)

Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS
by: Meng Li, et al.
Published: (2022-11-01)

Is the Combination Nirmatrelvir Plus Ritonavir Effective for Treating or Preventing COVID-19?
by: article Editorial
Published: (2022-12-01)

Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
by: Yuan-Pin Hung, et al.
Published: (2022-02-01)

Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study
by: Mei-Ping Chen, et al.
Published: (2024-02-01)

Clinical outcomes of nirmatrelvir-ritonavir use in pregnant women during the Omicron wave of the coronavirus disease 2019 pandemic
by: Chih-Wei Lin, et al.
Published: (2023-12-01)

Evaluation of nirmatrelvir + ritonavir therapy in patients with mild to moderate COVID-19
by: T.M. Levina, et al.
Published: (2024-03-01)

Does Nirmatrelvir/Ritonavir Influence the Immune Response against SARS-CoV-2, Independently from Rebound?
by: Francesca Panza, et al.
Published: (2023-10-01)

Nirmatrelvir/Ritonavir Utilization for the Treatment of Non-hospitalized Adults with COVID-19 in the National Veterans Affairs (VA) Healthcare System
by: Haley J. Appaneal, et al.
Published: (2024-01-01)

Real-World Experience of the Comparative Effectiveness and Safety of Molnupiravir and Nirmatrelvir/Ritonavir in High-Risk Patients with COVID-19 in a Community Setting
by: Yoshikazu Mutoh, et al.
Published: (2023-03-01)

Effectiveness of molnupiravir vs nirmatrelvir-ritonavir in non-hospitalised and hospitalised patients with COVID-19: a target trial emulation studyResearch in context
by: Eric Yuk Fai Wan, et al.
Published: (2023-10-01)

Case report: Supratherapeutic tacrolimus concentrations with nirmatrelvir/ritonavir in a lung transplant patient: a case report using Rifampin for reversal
by: Yu Xiong, et al.
Published: (2023-11-01)

Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
by: Seyed Mohammad Reza Hashemian, et al.
Published: (2023-06-01)

Overview of Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer
by: Kaleem Anwar, PharmD, et al.
Published: (2023-02-01)

The Antiviral Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data
by: Vasilios Petrakis, et al.
Published: (2023-04-01)

Real-World Study on Effectiveness of Molnupiravir and Nirmatrelvir–Ritonavir in Unvaccinated Patients with Chronic Respiratory Diseases with Confirmed SARS-CoV-2 Infection Managed in Out-Patient Setting
by: Wang Chun Kwok, et al.
Published: (2023-02-01)

Effectiveness of Oral Nirmatrelvir/Ritonavir vs. Intravenous Three-Day Remdesivir in Preventing Progression to Severe COVID-19: A Single-Center, Prospective, Comparative, Real-Life Study
by: Dimitrios Basoulis, et al.
Published: (2023-07-01)

Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching
by: An-Hua Wei, et al.
Published: (2023-10-01)

Adaptative Strategy of Immunosuppressive Drugs Dosage Adjustments When Combined With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients With COVID-19
by: Lidvine Boland, et al.
Published: (2024-03-01)

Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19
by: Federico Baldi, et al.
Published: (2023-01-01)

Modelling the end of a Zero-COVID strategy using nirmatrelvir/ritonavir, vaccination and NPIs in Wallis and FutunaResearch in context
by: Antoine Brault, et al.
Published: (2023-01-01)

Homogeneous liquid–liquid microextraction coupled with HPLC/DAD for determination of nirmatrelvir and ritonavir as COVID-19 combination therapy in human plasma
by: Inas A. Abdallah, et al.
Published: (2023-11-01)

Estudio de utilización de nirmatrelvir/ritonavir en tres centros de atención primaria durante 2022
by: José Miguel Sotoca-Momblona, et al.
Published: (2023-11-01)

Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease
by: Marta Colaneri, et al.
Published: (2024-03-01)

A case report of drug interaction between co-packaged nirmatrelvir-ritonavir and tacrolimus causing hyponatremia in a lung transplant recipient
by: Chien-Ming Lo, et al.
Published: (2024-03-01)